AFIX to Improve HPV Vaccination
- Conditions
- Papillomavirus VaccinesAdolescent Health Services
- Interventions
- Other: AFIX webinar consultationOther: AFIX in-person consultation
- Registration Number
- NCT02370459
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Brief Summary
The University of North Carolina will test the effectiveness of the Centers for Disease Control and Prevention's AFIX model for increasing HPV vaccination coverage among adolescents. AFIX (Assessment, Feedback, Incentives and eXchange) consists of brief quality improvement consultations that immunization specialists from state health departments deliver to vaccine providers in primary care settings. Using immunization registry data, the specialist evaluates the clinic's vaccination coverage and delivers education on best practices to improve coverage. We will compare changes in HPV vaccination coverage before and after consultations for high-volume pediatric and family medicine clinics across three study conditions: traditional consultations (in-person group), virtual consultations (webinar group), or no consultations (control group). In each participating state, 30 clinics will be randomly assigned to each study arm, for a total of 90 clinics per state, or 270 clinics overall. The primary objective of this study is to compare the change in coverage for HPV vaccine initiation among 11-12 year old patients, from baseline to 6-month follow-up. Secondarily, we will compare the change in coverage for other vaccines and age groups.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 223
Pediatric or family medicine clinics or practices in WA, IL, or MI with
- at least 500 active records for patients, ages 11-17, in their states' immunization information systems.
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description AFIX webinar consultation AFIX webinar consultation This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90. Clinics randomly assigned to this arm will receive an AFIX consultation via interactive webinar. Consultations will be delivered by state health department staff. AFIX in-person consultation AFIX in-person consultation This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90 clinics. Clinics randomly assigned to this arm will receive an in-person AFIX consultation. Consultations will be delivered by state health department staff.
- Primary Outcome Measures
Name Time Method HPV vaccination (≥1 dose), 11-12 year olds Six months Coverage change from baseline to six months in HPV vaccine initiation (≥1 dose), among 11- to 12-year old patients in the control arm versus the combined in-person and webinar intervention arms, as measured by electronic immunization information system (IIS) records, controlling for child's sex
- Secondary Outcome Measures
Name Time Method HPV vaccination (≥1 dose), 11-12 year olds Twelve months Coverage change from baseline to twelve months in HPV vaccine initiation (≥1 dose), among 11- to 12-year-old patients in the webinar versus in-person intervention arm, as measured by IIS records.
HPV vaccination (≥1 dose), 13-17 year olds Twelve months Coverage change from baseline to twelve months in HPV vaccine initiation (≥1 dose), among 13- to 17-year-old patients in the webinar versus in-person intervention arm, as measured by IIS records.
Meningococcal vaccination (≥1 dose), 13-17 year olds Twelve months Coverage change from baseline to twelve months in meningococcal vaccination (≥1 dose), among 13- to 17-year-old patients in the webinar versus in-person intervention arm, as measured by IIS records.
Tdap vaccination, 11-12 year olds Twelve months Coverage change from baseline to twelve months in Tdap vaccination among 11- to 12-year-old patients in the webinar versus in-person intervention arm, as measured by IIS records.
HPV vaccination (3 doses), 11-12 year olds Twelve months Coverage change from baseline to twelve months in HPV vaccine completion (3 doses), among 11- to 12-year-old patients in the webinar versus in-person intervention arm, as measured by IIS records.
Tetanus, diphtheria, and acellular pertussis (Tdap) vaccination, 11-12 year olds Six months Coverage change from baseline to six months in Tdap vaccination among 11- to 12-year-old patients in the control arm versus the combined in-person and webinar intervention arms, as measured by IIS records.
Meningococcal vaccination (≥1 dose), 11-12 year olds Twelve months Coverage change from baseline to twelve months in meningococcal vaccination (≥1 dose), among 11- to 12-year-old patients in the webinar versus in-person intervention arm, as measured by IIS records.
HPV vaccination (3 doses), 13-17 year olds Twelve months Coverage change from baseline to twelve months in HPV vaccine completion (3 doses), among 13- to 17-year-old patients in the webinar versus in-person intervention arm, as measured by IIS records.
Tdap vaccination, 13-17 year olds Twelve months Coverage change from baseline to twelve months in Tdap vaccination among 13- to 17-year-old patients in the webinar versus in-person intervention arm, as measured by IIS records.
Trial Locations
- Locations (4)
Illinois Department of Public Health
🇺🇸Springfield, Illinois, United States
Washington State Department of Health
🇺🇸Olympia, Washington, United States
Michigan Department of Community Health
🇺🇸Lansing, Michigan, United States
University of North Carolina
🇺🇸Chapel Hill, North Carolina, United States